Dova Pharmaceuticals Announces the Appointment of Mark W. Hahn as Chief Financial Officer | Markets Insider
DURHAM, N.C., Jan. 30, 2018 (GLOBE NEWSWIRE) — Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) today announced the appointment of Mark W. Hahn as the company’s Chief Financial Officer. A veteran Chief Financial Officer of the biotech industry, Mr. Hahn previously served as the Chief Financial officer of Cempra, Inc.
Name: Doug Blankenship
Continent: North America
Company: Dova Pharmaceuticals
Announcement Date: January 29, 2018, 11:00pm
Resignation Date: January 29, 2018, 11:00pm